Thermo Fisher Scientific: A Good Buy Near The Bottom


  • Thermo Fisher Scientific is facing temporary revenue headwinds due to reduced COVID-19-related sales and cautious customer spending.
  • The company’s organic revenues are expected to bottom in FY24 and see a reacceleration in growth from FY25 onwards which can help the stock re-rate.
  • TMO’s valuation is cheap compared to historical averages and peers, offering a good buying opportunity.

Thermo Fisher Scientific office in Whitby, On, Canada.


Investment Thesis

While Thermo Fisher Scientific Inc. (NYSE:TMO) is facing near-term revenue headwinds due to reduced COVID-19-related sales and cautious customer spending, these headwinds are temporary and the company’s organic revenues should bottom in FY24. The company continues to outperform

Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

This article is written by Ashish S.

Seeking Alpha’s Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Leave a Reply

Your email address will not be published. Required fields are marked *